Diabetes mellitus type 1 Diagnostic study of choice

Diabetes mellitus main page
Diabetes mellitus type 1 Microchapters
Home
Patient Information
Overview
Historical Perspective
Pathophysiology
Classification
Causes
Differentiating Diabetes mellitus type 1 from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural history, Complications, and Prognosis
Diagnosis
Diagnostic study of choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Dietary Management
Medical Therapy
Surgery
Strategies for Improving Care
Foundations of Care and Comprehensive Medical Evaluation Diabetes Self-Management, Education, and Support Nutritional Therapy
Glycemic Targets
Approaches to Glycemic Treatment
Cardiovascular Disease and Risk Management Hypertension and Blood Pressure Control Lipid Management Antiplatelet Agents Coronary Heart Disease
Microvascular Complications and Foot Care Diabetic Kidney Disease Diabetic Retinopathy Diabetic Neuropathy Diabetic Footcare
Older Adults with Diabetes
Children and Adolescents with Diabetes Management of Cardiovascular Risk Factors in Children and Adolescents with Diabetes Microvascular Complications in Children and Adolescents with Diabetes
Management of Diabetes in Pregnancy
Diabetes Care in the Hospital Setting
Primary Prevention
Future or Investigational Therapies
Case Studies
Case #1

Diabetes mellitus Main page
Patient Information Type 1 Type 2
Overview
Classification Diabetes mellitus type 1 Diabetes mellitus type 2 Gestational diabetes
Differential Diagnosis
Complications
Screening
Diagnosis
Prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Trusha Tank, M.D.[2];Hibatullah Abdul Aleem, M.B.B.S[3]

Overview

The diagnosis of diabetes mellitus is established by fasting plasma glucose (FPG) ≥126 mg/dL, 2-hour plasma glucose ≥200 mg/dL during an OGTT, HbA1c ≥6.5%, or a random plasma glucose ≥200 mg/dL with classic symptoms of hyperglycemia. Establishing diabetes is only the first step; classification as type 1 diabetes mellitus (T1DM) requires integration of clinical features, islet autoantibodies, and C-peptide. Because dysglycemia can progress rapidly in T1DM, plasma glucose is preferred over HbA1c for diagnosing acute-onset disease. T1DM is now recognized as a staged autoimmune disease (stages 1-3), and identification of presymptomatic disease has become clinically actionable with the approval of disease-modifying therapy.

Diagnostic Study of Choice

Gold standard or study of choice

• There is no single diagnostic study of choice for type 1 diabetes mellitus (T1DM). Diagnosis proceeds in two steps:
  1. Confirming the presence of diabetes mellitus using standard plasma glucose or HbA1c criteria.
  2. Classifying the diabetes subtype as T1DM using islet autoantibody testing combined with C-peptide measurement.
• Among patients with confirmed diabetes and phenotypic features suggestive of T1DM, islet autoantibody testing (GAD65, IA-2, ZnT8, and IAA in children) is the most specific set of tests used to establish the diagnosis, since 90-95% of individuals with T1DM have at least one positive autoantibody at diagnosis.
• C-peptide measurement, obtained with a concomitant glucose >72 mg/dL, is used as a complementary study to assess residual endogenous insulin secretion and to help resolve cases where autoantibody results are equivocal or negative.
• Because dysglycemia can progress rapidly in T1DM, plasma glucose (fasting, random with symptoms, or OGTT) should be used preferentially over HbA1c when acute-onset T1DM is suspected, since HbA1c may underestimate the degree of hyperglycemia in this setting.

The comparison table for diagnostic studies of choice for type 1 diabetes mellitus

	Sensitivity	Specificity
GAD65 antibody	66-82%	97-99%
IA-2 antibody	76-78%	✔ (~100%)
ZnT8 antibody	56-76%	99-100%
Insulin autoantibodies (IAA)	52-54%	99-100%
Any islet autoantibody positive	✔ (90-95%)	Varies by number positive

✔= The best test based on the feature

Diagnostic results

The following results are confirmatory of type 1 diabetes mellitus:

• Diabetes confirmed by ADA glycemic criteria and at least one positive islet autoantibody (GAD65, IA-2, ZnT8, or IAA).
• Undetectable or very low C-peptide, consistent with severe insulin deficiency (though C-peptide may still be normal early in the disease course).
• In adults <35 years: C-peptide <200 pmol/L (0.6 ng/mL) within 5 hours of a meal combined with ≥1 positive islet autoantibody is suggestive of T1DM.
• C-peptide values of 200-600 pmol/L represent a diagnostic gray zone requiring clinical judgment, whereas C-peptide ≥600 pmol/L (1.8 ng/mL) in an insulin-treated adult >35 years is most consistent with type 2 diabetes rather than T1DM.

Sequence of Diagnostic Studies

Islet autoantibody and C-peptide testing should be performed when:

• Diabetes has already been confirmed biochemically (FPG, OGTT, HbA1c, or random glucose with symptoms), and
• The patient has phenotypic features overlapping T1DM summarized by the ADA "AABBCC" mnemonic: Age <35 years, Autoimmunity (personal/family history), Body habitus (BMI <25 kg/m²), Background (family history of T1DM), Control (failure of glycemic goals on noninsulin therapy), and Comorbidities (e.g., checkpoint inhibitor-associated diabetes).
• Testing should not be performed within 2 weeks of resolution of DKA or severe hyperglycemia, and C-peptide should be drawn with a concomitant glucose >72 mg/dL, since hypoglycemia suppresses C-peptide secretion.
• Autoantibody testing should be interpreted cautiously (risk of false-negative/masked results) if the patient is on corticosteroids or immunosuppressants.

Diagnostic Approach

Suspected diabetes

Symptomatic (polyuria, polydipsia, weight loss, DKA)

Asymptomatic

Random plasma glucose ≥200 mg/dL confirms diabetes

FPG or HbA1c preferred; two abnormal results required to confirm

Diabetes confirmed → classify subtype

Measure islet autoantibodies (GAD65, IA-2, ZnT8; IAA in children) + C-peptide with concurrent glucose

Autoantibody-positive → T1DM

Autoantibody-negative → assess C-peptide, clinical features; consider LADA, MODY, T2DM

Abbreviations: DKA = diabetic ketoacidosis; FPG = fasting plasma glucose; GAD65 = glutamic acid decarboxylase 65; HbA1c = glycosylated hemoglobin; IA-2 = insulinoma-associated antigen 2; IAA = insulin autoantibodies; LADA = latent autoimmune diabetes in adults; MODY = maturity-onset diabetes of the young; T1DM = type 1 diabetes mellitus; T2DM = type 2 diabetes mellitus; ZnT8 = zinc transporter 8.

Diagnostic Criteria

Diagnostic Criteria for Diabetes Mellitus (ADA)

The diagnosis of diabetes mellitus is established by the ADA when at least one of the following criteria is met (confirmed by a second abnormal result, either from the same sample or a separate time point, unless unequivocal hyperglycemia with classic symptoms is present):

ADA Criteria for the Diagnosis of Diabetes

Test	Diagnostic Threshold	Notes
Fasting plasma glucose (FPG)	≥126 mg/dL (7.0 mmol/L)	Fasting = no caloric intake for ≥8 hours; requires confirmatory testing if asymptomatic
2-hour plasma glucose (OGTT)	≥200 mg/dL (11.1 mmol/L)	75-g oral glucose load; more sensitive than FPG or HbA1c
HbA1c	≥6.5% (48 mmol/mol)	NGSP-certified, DCCT-standardized assay required
Random plasma glucose	≥200 mg/dL (11.1 mmol/L)	Only with classic symptoms of hyperglycemia or hyperglycemic crisis

If two different tests are discordant, the test above the diagnostic threshold should be repeated to confirm the diagnosis.

ADA Staging Criteria for Type 1 Diabetes

T1DM is classified by the ADA as a chronic autoimmune disease with three identifiable stages, based on autoantibody status, glycemia, and symptoms:

ADA Staging of Type 1 Diabetes

Stage	Autoantibodies	Glycemia	Symptoms	Progression Risk
Stage 1	≥2 islet autoantibodies	Normoglycemia	None	~44% at 5 years; ~100% lifetime
Stage 2	≥2 islet autoantibodies (usually)	Dysglycemia (impaired fasting glucose, impaired glucose tolerance, HbA1c 5.7-6.4%, or ≥200 mg/dL at 30/60/90 min on OGTT)	None	~60% at 2 years; ~75% at 5 years
Stage 3	May be present or absent	Meets diabetes diagnostic criteria	Often present	Clinical diabetes

This staging framework became clinically actionable with the FDA approval of teplizumab (TZIELD). The current FDA label indicates teplizumab for adult and pediatric patients aged ≥1 year with stage 2 T1DM to delay onset of stage 3 disease, and separately for pediatric patients aged 8-17 years with recently diagnosed stage 3 T1DM to delay the decline in endogenous insulin production. (Note: ADA 2026 Recommendation 3.17 [Level B] still references age ≥8 years for stage 2 treatment, so the guideline and the current label diverge; the FDA label is the authoritative regulatory source.) Detailed screening protocols and monitoring of autoantibody-positive individuals are covered in the Screening microchapter.

Latent Autoimmune Diabetes in Adults (LADA)

There is no single diagnostic study of choice for LADA, though LADA may be diagnosed based on the WHO definition of slowly evolving immune-related diabetes, as restated in the international expert consensus statement. LADA accounts for 2-12% of adult-onset diabetes. Affected individuals clinically resemble T2DM at diagnosis (not requiring insulin initially) but carry immunogenetic markers of T1DM; GAD65 is the most prevalent autoantibody. C-peptide-based treatment stratification has been proposed.